RARITAN, N.J., July 23, 2026
Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical trial, demonstrating that the investigational combination of TECVAYLI® (teclistamab-cqyv) and TALVEY® (talquetamab-tgvs) significantly improved outcomes for patients with relapsed or refractory multiple myeloma (RRMM). The dual-targeting immunotherapy regimen reduced the risk of disease progression or death by 89% and reduced the risk of death by 62% compared with standard-of-care treatments, representing the lowest hazard ratio reported in any Phase 3 bispecific antibody study in relapsed or refractory multiple myeloma. The findings further strengthen Johnson & Johnson’s leadership in multiple myeloma immunotherapy and support the continued expansion of innovative T-cell engager therapies into earlier treatment settings for patients who have received one to four prior lines of therapy.
Dual-Target Immunotherapy Delivers Landmark Clinical Results
The MonumenTAL-6 study is the first and only Phase 3 trial evaluating a dual-antigen strategy that simultaneously targets B-cell maturation antigen (BCMA) and GPRC5D in patients with relapsed or refractory multiple myeloma. The trial compared TECVAYLI® plus TALVEY® (Tec-Tal) and TALVEY® plus pomalidomide (Tal-P) against investigator-selected standard therapies, including elotuzumab, pomalidomide, dexamethasone (EPd) and pomalidomide, bortezomib, dexamethasone (PVd). Both investigational treatment arms achieved the study’s primary endpoint of progression-free survival, with the TECVAYLI® plus TALVEY® combination demonstrating the strongest benefit by reducing the risk of disease progression or death by 89%, while the TALVEY® plus pomalidomide regimen reduced the risk by 73%. Overall safety findings remained consistent with the known profiles of each therapy, and the strength of the efficacy data prompted the Independent Data Monitoring Committee (IDMC) to recommend unblinding the trial during the first interim analysis.
Immunotherapy Expands Earlier in Multiple Myeloma Car
The positive Phase 3 results reinforce the growing role of bispecific T-cell engager therapies in treating multiple myeloma, a complex blood cancer affecting plasma cells within the bone marrow. TECVAYLI® is a BCMA-directed bispecific antibody that activates T-cells to destroy myeloma cells, while TALVEY® targets GPRC5D, another highly expressed protein found on multiple myeloma cells. By combining these complementary mechanisms, Johnson & Johnson aims to generate deeper and more durable responses than single-target approaches. The company noted that this represents its fifth positive Phase 3 study supporting earlier use of its multiple myeloma immunotherapy portfolio, reflecting its strategy of offering physicians multiple treatment options across different stages of disease progression. These encouraging findings further strengthen evidence supporting immunotherapy combinations as a cornerstone of future multiple myeloma treatment.
Advertisement
Johnson & Johnson Strengthens Leadership in Myeloma Innovation
Johnson & Johnson continues to expand one of the industry’s broadest multiple myeloma portfolios, spanning CD38-directed therapies, BCMA-targeting antibodies, GPRC5D-targeting bispecific antibodies, and cell therapies. More than 180,000 new cases of multiple myeloma are diagnosed globally each year, making continued therapeutic innovation essential for improving patient survival and quality of life. Building upon previous regulatory approvals for TECVAYLI® and TALVEY®, the company intends to present complete MonumenTAL-6 data at an upcoming major medical conference while engaging global regulatory authorities regarding future development plans. If confirmed through full data presentation and regulatory review, the combination of TECVAYLI® and TALVEY® could represent a significant advancement in earlier-line treatment for relapsed or refractory multiple myeloma and further support Johnson & Johnson’s long-term vision of transforming this challenging blood cancer into a disease with increasingly durable outcomes and, ultimately, the potential for cure.
Source: Johnson & Johnson press release
